A report released Feb. 29th by the Institute of Medicine (IOM) provided a review of the benefits of current federal laws that offer incentives for or require drug and biologic developers to conduct pediatric studies. The report also highlighted several areas where...
This event will be a great gathering for clinical research professionals. Gretchen Bowker, Pearl IRB COO is speaking at the event. The title of the event is: Ask the IRB’s- Answers might be different than what your IRB is telling you. Pearl will also be...
The current worldwide economic downturn is continuing to shrink the number of investigative sites across the globe. The sharpest decline in investigator sites has occurred in Europe according to CenterWatch. The US is not immune to this activity as the most active...
Our office will be closed for the holidays December 23rd through December 26th, 2011 and also on January 2nd, 2012. We will hold no regular IRB Board meeting the week of December 26th. If you need to talk to us about your need for an urgent review, just contact us...
Our office will be closed for the Thanksgiving Holiday on November 24th and 25th. We will hold no regular IRB Board meeting the week of November 21st. If you need to talk to us about your need for an urgent review, just contact us and we will see what we can do. ...
We are thrilled to have Rachel Ochs-Ross, M.D., J.D. join our Board as co-chair. She is an experienced Neurologist who has extensive experience guiding all phases of clinical drug development, from early compound assessment through Phase IV clinical studies and has...
